JP2016513677A - ムスカリンアゴニスト - Google Patents

ムスカリンアゴニスト Download PDF

Info

Publication number
JP2016513677A
JP2016513677A JP2016502306A JP2016502306A JP2016513677A JP 2016513677 A JP2016513677 A JP 2016513677A JP 2016502306 A JP2016502306 A JP 2016502306A JP 2016502306 A JP2016502306 A JP 2016502306A JP 2016513677 A JP2016513677 A JP 2016513677A
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
octane
disease
indazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513677A5 (enExample
Inventor
エス．ブルステイン エサン
エス．ブルステイン エサン
エスキルドセン ジョルゲン
エスキルドセン ジョルゲン
オルソン ロジャー
オルソン ロジャー
エム．ルフルス ローレン
エム．ルフルス ローレン
エー．ホイーラー ラリー
エー．ホイーラー ラリー
ダブリュー．ギル ダニエル
ダブリュー．ギル ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2016513677A publication Critical patent/JP2016513677A/ja
Publication of JP2016513677A5 publication Critical patent/JP2016513677A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emergency Medicine (AREA)
JP2016502306A 2013-03-15 2014-03-14 ムスカリンアゴニスト Pending JP2016513677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790364P 2013-03-15 2013-03-15
US61/790,364 2013-03-15
PCT/US2014/026998 WO2014152144A1 (en) 2013-03-15 2014-03-14 Muscarinic agonists

Publications (2)

Publication Number Publication Date
JP2016513677A true JP2016513677A (ja) 2016-05-16
JP2016513677A5 JP2016513677A5 (enExample) 2017-04-13

Family

ID=50439523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502306A Pending JP2016513677A (ja) 2013-03-15 2014-03-14 ムスカリンアゴニスト

Country Status (13)

Country Link
US (1) US9670209B2 (enExample)
EP (1) EP2976079A1 (enExample)
JP (1) JP2016513677A (enExample)
KR (1) KR20150143439A (enExample)
CN (1) CN105120865A (enExample)
AU (1) AU2014240139A1 (enExample)
BR (1) BR112015021271A2 (enExample)
CA (1) CA2903276A1 (enExample)
IL (1) IL241001A0 (enExample)
MX (1) MX2015012043A (enExample)
RU (1) RU2015144155A (enExample)
TW (1) TW201446761A (enExample)
WO (1) WO2014152144A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670209B2 (en) 2013-03-15 2017-06-06 Acadia Pharmaceuticals Inc. Muscarinic agonists
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US9822122B2 (en) 2016-03-31 2017-11-21 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152470A (ja) * 1996-09-25 1998-06-09 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
JP2003531901A (ja) * 2000-04-28 2003-10-28 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン性アゴニスト
JP2006521399A (ja) * 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト
JP2008524328A (ja) * 2004-12-21 2008-07-10 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン作動薬としてのテトラヒドロキノリン類似体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707798A (en) 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
EP1535912A1 (en) 2000-04-28 2005-06-01 Arcadia Pharmaceuticals Inc. Muscarinic agonists
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US9670209B2 (en) 2013-03-15 2017-06-06 Acadia Pharmaceuticals Inc. Muscarinic agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10152470A (ja) * 1996-09-25 1998-06-09 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
JP2003531901A (ja) * 2000-04-28 2003-10-28 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン性アゴニスト
JP2006521399A (ja) * 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト
JP2008524328A (ja) * 2004-12-21 2008-07-10 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン作動薬としてのテトラヒドロキノリン類似体

Also Published As

Publication number Publication date
US9670209B2 (en) 2017-06-06
CA2903276A1 (en) 2014-09-25
KR20150143439A (ko) 2015-12-23
WO2014152144A1 (en) 2014-09-25
TW201446761A (zh) 2014-12-16
EP2976079A1 (en) 2016-01-27
BR112015021271A2 (pt) 2017-08-22
US20160039819A1 (en) 2016-02-11
AU2014240139A1 (en) 2015-09-17
CN105120865A (zh) 2015-12-02
MX2015012043A (es) 2016-03-17
IL241001A0 (en) 2015-11-30
RU2015144155A (ru) 2017-04-24

Similar Documents

Publication Publication Date Title
CN104370914B (zh) 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
KR102072850B1 (ko) 브로모도메인 억제제로서의 벤즈이미다졸 유도체
KR100191973B1 (ko) 5-아릴인돌 유도체
US7238713B2 (en) Muscarinic agonists
KR100364306B1 (ko) 다환 아민 화합물 및 그의 거울이성질체
KR101060892B1 (ko) Ｐｋｃ 억제제로서의 3-아미노-피롤로[3,4-ｃ] 피라졸-5(1ｈ,4ｈ,6ｈ) 카브알데하이드 유도체
JP4607457B2 (ja) ピロロピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用
TW201406765A (zh) 經雜環取代之六氫哌喃並［３，４－ｄ］［１，３］噻□－２－胺化合物類
CN104684915A (zh) 新型双环衍生物
TW200401774A (en) Substituted quinoline CCR5 receptor antagonists
WO2001025228A1 (en) Amine derivatives
CN115413279A (zh) P2x3调节剂
KR100830763B1 (ko) 피페리디닐카보닐-피롤리딘 및 멜라노코르틴 작용제로서의그의 용도
US20170327493A1 (en) Cxcr7 receptor modulators
CN101646673B (zh) 作为pkc抑制剂的3-氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
CN111971282A (zh) 作为多巴胺d1受体正向调节剂的吡唑并四氢异喹啉衍生物
JP6837072B2 (ja) ６，７−ジヒドロ−５Ｈ−ピラゾロ［５，１−ｂ］［１，３］オキサジン−２−カルボキサミド化合物
KR19990076616A (ko) 2,7-치환된 옥타하이드로-피롤로[1,2-에이]피라진 유도체
JP2016513677A (ja) ムスカリンアゴニスト
WO2008039087A2 (en) Indoline derivatives and uses thereof
WO2018188785A1 (en) Compound, compound for use in the treatment of a pathological condition, a pharmaceutical composition and a method for preparing said compound
CN109843379B (zh) 取代脲及其制备和使用方法
KR20220042379A (ko) 키티나제 억제제로서 유용한 치환된 아미노 트리아졸
JP7422242B2 (ja) マクロサイクル化合物
RU2818822C1 (ru) Макроциклическое соединение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180911